Q1 EPS Estimates for MAIA Biotechnology Raised by Analyst

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) – Research analysts at Diamond Equity lifted their Q1 2025 earnings estimates for shares of MAIA Biotechnology in a note issued to investors on Tuesday, March 25th. Diamond Equity analyst H. Diamond now forecasts that the company will post earnings of ($0.18) per share for the quarter, up from their prior estimate of ($0.25). The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($1.30) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.13) EPS and FY2025 earnings at ($0.75) EPS.

MAIA Biotechnology Price Performance

NYSEAMERICAN:MAIA opened at $1.63 on Thursday. MAIA Biotechnology has a 12-month low of $1.46 and a 12-month high of $5.99. The business has a fifty day moving average of $1.85. The company has a market cap of $42.64 million, a price-to-earnings ratio of -1.18 and a beta of 0.20.

Institutional Trading of MAIA Biotechnology

Institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd bought a new stake in shares of MAIA Biotechnology in the 3rd quarter valued at $31,000. Geode Capital Management LLC grew its stake in MAIA Biotechnology by 22.9% in the third quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock valued at $541,000 after acquiring an additional 35,821 shares during the period. Finally, Jane Street Group LLC acquired a new position in MAIA Biotechnology in the fourth quarter valued at about $77,000. 5.65% of the stock is owned by institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.